Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

116.07 -0.14 (-0.12%)

Streaming Delayed Price Updated: 3:31 PM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Is Merck Stock a Buy? ↗

February 22, 2025

Via The Motley Fool

Law Offices of Howard G. Smith Encourages Merck & Co (MRK) Investors To Inquire About Securities Fraud Class Action

February 21, 2025

From Law Offices of Howard G. Smith

Via Business Wire

2 Healthcare Stocks with Big Upside and 1 to Skip

February 21, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Looking Into Merck & Co's Recent Short Interest ↗

February 18, 2025

Via Benzinga

Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock ↗

February 18, 2025

Via Benzinga

Why NYSE:MRK is a Top Pick for Dividend Investors. ↗

February 18, 2025

Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals.

Via Chartmill

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

February 20, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

February 20, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Merck & Co (MRK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

February 20, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Decoding Merck & Co's Options Activity: What's the Big Picture? ↗

February 13, 2025

Via Benzinga

Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks

February 20, 2025

Check out these three mega-cap names, valued over $200 billion each, that just authorized a combined $28 billion in buybacks.

Via MarketBeat

Topics Earnings Economy Intellectual Property

ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies ↗

February 20, 2025

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

Via Stocktwits

Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

February 19, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

February 19, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors.

Via Benzinga

Topics ETFs Government World Trade

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

February 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK

February 18, 2025

From Robbins LLP

Via GlobeNewswire

Europe Approves Merck's Cancer Drug For Two Indications ↗

February 18, 2025

Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries.

Via Benzinga

This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

February 18, 2025

Via Benzinga

Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

February 18, 2025

Via Benzinga

WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications

February 18, 2025

From Merck & Co., Inc.

Via Business Wire

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗

February 18, 2025

Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion.

Via Benzinga

Topics Government

MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 17, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 17, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 15, 2025

From The Schall Law Firm

Via Business Wire

MarketBeat Week in Review – 02/10 - 02/14

February 15, 2025

Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in

Via MarketBeat

Topics Credit Cards Economy Government

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 14, 2025

Via Benzinga

In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals. ↗

February 14, 2025

MERCK & CO. INC. has caught the attention as a great value stock. NYSE:MRK excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 14, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.